Medical device maker Boston Scientific Corporation (NYSE: BSX) reported financial results for the second quarter of 2023. The company also provided guidance for fiscal 2023.
- The company reported net sales of $3.599 billion for Q2, representing an 11% year-over-year increase, and an 11.6% growth on an organic basis
- Net income attributable to stockholders, on an unadjusted basis, was $261 million, compared to $246 million in the year-ago period
- Net income per share came in at $0.18 per share, slightly higher than the $0.17 per share reported last year
- Second-quarter adjusted earnings increased to $0.53 per share from $0.44 per share in the same period of last year
- The management expects net sales to grow in the range of 10.5% to 11.5% in fiscal 2023 on a reported basis, and 10-11% on an organic basis
- Full-year net income, including special items, is expected to be between $0.87 per share and $0.93 per share; the forecast for adjusted EPS is $1.96-$2.00
Most Popular
USB Earnings: US Bancorp Q1 profit jumps on higher interest income
U.S. Bancorp (NYSE: USB) Wednesday reported a double-digit growth in first-quarter earnings, reflecting an increase in net interest income. Total net revenue increased 3.6% from last year to $7.0 billion
Abbott Laboratories (ABT) Q1 2025 Earnings: Key financials and quarterly highlights
Abbott Laboratories (NYSE: ABT) reported its first quarter 2025 earnings results today. Total sales increased 4% year-over-year to $10.35 billion. Organic sales growth was 6.9%. Net earnings grew 8.2% to
UAL Earnings: Highlights of United Airlines’ Q1 2025 financial results
Aviation giant United Airlines Holdings, Inc. (NYSE: UAL) on Tuesday announced financial results for the first quarter of 2025. Net income, on an adjusted basis, was $0.91 per share in
